Somatrogon - Wikipedia
Somatrogon, sold under the brand name Ngenla, is a medication for the treatment of growth hormone deficiency. [1] [6] [8] Somatrogon is a glycosylated protein constructed from human growth hormone and a small part of human chorionic gonadotropin which is appended to both the N-terminal and C-terminal. [8] Somatrogon is a human growth hormone ...
Somatrogon: First Approval - PubMed
Somatrogon (NGENLA ®), a long-acting human growth hormone based on C-terminal peptide technology, is in development by Pfizer and OPKO Health for the treatment of growth hormone deficiency in pediatric and adult patients. Administered as a once-weekly subcutaneous injection, somatrogon reduces treatment burden relative to once-daily human ...
Somatrogon: Uses, Interactions, Mechanism of Action - DrugBank …
2019年5月20日 · Somatrogon is a long-acting recombinant human growth hormone used as the long-term treatment of pediatric patients who have growth failure due to growth hormone deficiency.
Somatrogon: First Approval | Drugs - Springer
2022年1月18日 · Somatrogon, a glycoprotein produced in Chinese Hamster Ovary cells via recombinant DNA technology, consists of the human growth hormone amino acid sequence with one copy of the C-terminal peptide (CTP) derived from human chorionic gonadotropin at the N-terminus and two copies of CTP at the C-terminus [2].
Clinical Review - Somatrogon (Ngenla) - NCBI Bookshelf
Somatrogon is a modified long-acting analogue of human growth hormone (hGH). It is a new molecular entity with receptor-binding properties and a mechanism of action analogous to hGH. 10 Somatrogon binds to the GH receptor and initiates a signal transduction cascade, culminating in changes in growth and metabolism.
Ngenla | European Medicines Agency (EMA)
2022年3月2日 · The active substance in Ngenla, somatrogon, is a version of natural human growth hormone which has been modified by combining it with part of another human hormone called chorionic gonadotropin in a so-called recombinant hormone.
Somatrogon - PubChem
Somatrogon is a hormone replacement therapy that aims to restore deficient levels of growth hormone (GH). Like endogenous growth hormone, somatrogon binds to the GH receptor, which leads to the binding of JAK2 to GH receptor and activation of JAK2.
Somatrogon in paediatric growth hormone deficiency: a profile of …
2022年11月18日 · Somatrogon (NGENLA®), a modified long-acting form of recombinant human growth hormone (rhGH), is a valuable new option for the treatment of paediatric patients aged ≥ 3 years with growth disturbance due to insufficient GH secretion in the EU, and offers the convenience of once-weekly administration.
Somatrogon (NGENLA®), a long-acting human growth hormone based on C-terminal peptide technology, is in development by Pfizer and OPKO Health for the treatment of growth hormone deficiency in pediatric and adult patients.
Somatrogon for growth hormone deficiency - PMC - National …
2022年9月1日 · In children, growth hormone deficiency may be congenital, acquired or idiopathic. It has several effects including reduced growth resulting in short stature. The children are treated with synthetic human growth hormone (somatropin). This requires daily injections which are painful and distressing for some children.